World's Best Scientists 2026 revealed!
Victoria M. Richon

Victoria M. Richon

D-Index & Metrics

Biology and Biochemistry

D-Index
84
Citations
41361
World Ranking
3236
National Ranking
1638

Victoria M. Richon publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Victoria M. Richon sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 185 publications — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Victoria M. Richon D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Victoria M. Richon sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 84 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Victoria M. Richon is affiliated with Entact Bio in the United States and has contributed significantly to cancer research, focusing particularly on PARP inhibition in cancer therapy. Their research spans multiple aspects of oncology, molecular biology, epidemiology, physiology, and immunology, with a concentration on signaling pathways and immune responses relevant to cancer treatment.

Their recent publications reflect a focus on the role of PARP enzymes and their inhibition in cancer models and immune signaling. These papers include:

  • PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity, 2021, Cancer Cell
  • A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants, 2021, Cell Chemical Biology
  • Abstract DDT02-01: RBN-2397: A first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways, 2020, Cancer Research
  • Abstract 2154: PARP7 inhibitor RBN-2397 increases tumoral IFN signaling leading to various tumor cell intrinsic effects and tumor regressions in mouse models, 2022, Cancer Research
  • The PARP14 inhibitor RBN-3143 suppresses lung inflammation in preclinical models, 2022, 05.01 - Airway pharmacology and treatment

The primary themes in their work concentrate on:

  • PARP inhibition in cancer therapy
  • Interferon and immune responses
  • Cancer immunotherapy and biomarkers
  • Signaling pathways in disease
  • Autophagy in disease and therapy
  • Antimicrobial resistance in Staphylococcus
  • Calcium signaling and nucleotide metabolism

Victoria M. Richon has collaborated extensively with several scientists, with frequent co-authors including Melissa M. Vasbinder, Mario Niepel, Kevin W. Kuntz, Ryan Abo, and Kristy Kuplast-Barr.

The bulk of their publications have appeared mainly in the venues of Cancer Research, Cancer Cell, and Cell Chemical Biology, with seven publications in Cancer Research and individual contributions to other specialized journals.

Their expertise lies predominantly within the field of Medicine, with 13 documented publications. Subfields show a strong emphasis on Oncology, reflected in 10 publications, followed by studies in Molecular Biology, Epidemiology, Physiology, and Immunology.

Best Publications

  • Histone deacetylases and cancer: causes and therapies.

    Paul A. Marks;Richard A. Rifkind;Victoria M. Richon;Ronald Breslow

  • Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.

    Michael S. Finnin;Jill R. Donigian;Alona Cohen;Victoria M. Richon

  • Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells

    Paul A. Marks;Victoria M. Richon;Richard A. Rifkind

  • Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

    Victoria M. Richon;Todd W. Sandhoff;Richard A. Rifkind;Paul A. Marks

  • Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

    William Kevin Kelly;Owen A. O'Connor;Lee M. Krug;Judy H. Chiao

  • A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases

    Victoria M. Richon;Stephane Emiliani;Eric Verdin;Yael Webb

  • Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

    E. Hockly;V.M. Richon;B. Woodman;D.L. Smith

  • Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor

    Scott R. Daigle;Edward J. Olhava;Carly A. Therkelsen;Christina R. Majer

  • MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L

    Kathrin M. Bernt;Nan Zhu;Amit U. Sinha;Sridhar Vempati

  • A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

    Sarah K Knutson;Tim J Wigle;Natalie M Warholic;Christopher J Sneeringer

  • Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

    Sarah K. Knutson;Natalie M. Warholic;Tim J. Wigle;Christine R. Klaus

  • Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

    Lisa M. Butler;David B. Agus;Howard I. Scher;Brian Higgins

  • Histone deacetylase inhibitors as new cancer drugs.

    Paul A. Marks;Victoria M. Richon;Ronald Breslow;Richard A. Rifkind

  • Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

    Christopher J. Sneeringer;Margaret Porter Scott;Kevin W. Kuntz;Sarah K. Knutson

  • Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

    Scott R. Daigle;Edward J. Olhava;Carly A. Therkelsen;Aravind Basavapathruni

  • Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone Deacetylase

    Raymond P. Warrell;Li-Zhen He;Victoria Richon;Elizabeth Calleja

  • Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications

    Constantine S. Mitsiades;Nicholas S. Mitsiades;Ciaran J. McMullan;Vassiliki Poulaki

  • The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin

    Lisa M. Butler;Xianbo Zhou;Wei-Sheng Xu;Howard I. Scher

  • Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

    Melissa J. Peart;Gordon K. Smyth;Ryan K. van Laar;David D. Bowtell

  • Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

    V M Richon;Y Webb;R Merger;T Sheppard

Frequent Co-Authors

Robert A. Copeland
Robert A. Copeland Accent Therapeutics (United States)
Paul A. Marks
Paul A. Marks Columbia University
Richard A. Rifkind
Richard A. Rifkind Memorial Sloan Kettering Cancer Center
Ronald Breslow
Ronald Breslow Columbia University
Lisa M. Butler
Lisa M. Butler University of Adelaide
Scott A. Armstrong
Scott A. Armstrong Harvard University
George Sgouros
George Sgouros Johns Hopkins University
Kapil N. Bhalla
Kapil N. Bhalla The University of Texas MD Anderson Cancer Center
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Timothy J. Mitchison
Timothy J. Mitchison Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Victoria M. Richon

Trending Scientists

Recently Published Articles